Application of Radiolabeled Monoclonal A7 Antibody for Radioimmunotherapy of Human Colon Cancer
| Project/Area Number |
13470180
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
TONAMI Norihisa Kanazawa University, Graduate School of Medical Sciences, Professor, 大学院・医学系研究科, 教授 (60019940)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOKOYAMA Kunihiko Kanazawa University Hospital, Lecturer, 医学部附属病院, 講師 (60230661)
SHIBA Kazuhiro Kanazawa University, Advanced Science Research, Associate Professor, 学際科学実験センター, 助教授 (40143929)
|
|---|
| Project Period (FY) |
2001 – 2004
|
| Project Status |
Completed (Fiscal Year 2004)
|
| Budget Amount *help |
¥9,200,000 (Direct Cost: ¥9,200,000)
Fiscal Year 2004: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2003: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2002: ¥1,700,000 (Direct Cost: ¥1,700,000)
Fiscal Year 2001: ¥5,100,000 (Direct Cost: ¥5,100,000)
|
|---|
| Keywords | monoclonal antibody / radioimmunotherapy / colon cancer / radiolabeling / chelating agent / I-131 / Re-186 / Re-188 / In-111 |
|---|
| Research Abstract |
Using monoclonal antibody specific for tumor associated antigen expressed on human malignant tumor cells, therapeutic radionuclides can be delivered to the tumor lesion in vivo. For this approach, the stable radiometal chelates is required. Re-186 or Re-188 are expected to be the choice of radionuclide for radioimmunotherapy. We have assessed the conjugation procedure of the MAG3 chelate and HYNIC chelate. The stability of the radiolabel was found to be satisfactory. A monoclonal antibody A7 was used for the project. This antibody recognizes adenocarcinoma related antigen on the variety of human colon cancer cells. The A7 antibody was labeled with Re-186, resulting in the specific activity of greater than 37 MBq/mg. And the immunoreactivity of the labeled antibody was 67%, which is equivalent for that of I-131 labeled counterpart.
LS180 human colon cancer cells were inoculated to the Balb/c nude mice. In vivo imaging with either I-131 or Re-186 labeled A7 provided well-delineated tumor. Therapy trial study demonstrated that Re-186 A7 delivered 1.6 times higher radiation to the tumor than I-131 A7. Thus, Re-186 antibody should be the attractive modality for radioimmunotherapy.
We have tried to increase the tumor uptake of radiolabeled antibodies by modifying the delivery system to the tumor tissue. The combination usage of angiotensin-II and a kininase inhibitor, enalapril maleate, increased the mouse blood pressure from 95/61 to 153/67. And the tumor uptake was also increased by the factor of 1.62 with little change in normal organ distribution. In conclusions, enhanced tumor uptake was achieved by manipulating hemodynamics and vascular permeability of the tumor tissue and this technique can be applied for effective targeting.
|
Report
(5 results)
Research Products
(11 results)
-
-
-
-
-
[Journal Article] Improved survival of mice bearing liver metastases of colon cancer cells treated with combination of radioimmunotherapy and antiangiogenic therapy2004
Author(s)
Kinuya S, Yokoyama K, Koshida K, Mori H, Shiba K, Watanabe N, Shuke N, Bai J, Bunko H, Michigishi T, Tonami N
-
Journal Title
Eur J Nucl Med Mol Imaging 31
Pages: 981-985
Description
「研究成果報告書概要(欧文)」より
Related Report
-
-
-
[Journal Article] Radioimmunotherapy with 186Re-labeled monoclonal antibody to treat liver metastases of colon cancer cells in nude mice2002
Author(s)
Kinuya S, Yokoyama K, Kawashima A, Izumo M, Sorita T, Obata T, Watanabe N, Shuke N, Bunko H, Michigishi T, Tonami N
-
Journal Title
Cancer Brother Radiopharm 6
Pages: 681-688
Description
「研究成果報告書概要(欧文)」より
Related Report
-
-
-
